Brief: Diasorin Sees 2030 Adj EBITDA Margin At 34%-35%
20/05/2026 10:17
May 20 (Reuters) - DiaSorin SpA DIAS.MI: SEES 2026 REVENUE GROWTH OF 5%-6%, 2026-2030 CAGR OF 6%-8% SEES 2026 ADJUSTED EBITDA MARGIN AT 32%-33%, 2030 AT 34%-35% SEES CUMULATIVE FREE CASH FLOW 2027-2030 AT ABOUT €1 BILLION Further company coverage: DIAS.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Diasorin
See all newsEquita upgrades Diasorin, sees 'solid' Q3
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21